The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
MJFF Research Grant, 2010PROGENI Family Study
Objective/Rationale:
The LRRK2 Consortium is designing studies to allow researchers to identify the key genetic, biological and clinical features of LRRK2 associated PD that could lead to improved... -
Alpha-Synuclein Therapeutics, 2010Anti-amyloid Oligomer Monoclonal Antibodies for Treatment of Parkinson's Disease
Objective/Rationale:
The goal of this project is to evaluate the interaction of a panel of conformation dependent, aggregation specific anti-amyloid monoclonal antibodies with alpha-synuclein... -
Pharmacodynamic Biomarkers of LRRK2 Activity, 2010LRRK2 Dimerization as Pharmacodynamic Biomarkers of Activity
Objective/Rationale:
A promising target for neuroprotective therapies in Parkinson’s disease has emerged in the LRRK2 protein kinase. Proteins with similarities to LRRK2 have been successfully... -
Novel Hypotheses in Parkinson's Disease, 2010Quantitative Analysis of S-Nitrosylated Proteins in Parkinson's Disease
Objective/Rationale:
Free radical stress may play a role in pathogenesis of Parkinson’s disease (PD). In this project, we study how free radicals related to reactive nitrogen (N) and oxygen (O)... -
Understanding LRRK2 Biology, 2010Functional Analysis of LRRK2: Focus on Autophagy
Promising Outcomes of Original Grant:
The overall purpose of the original grant was to utilize pre-clinical and human model systems to better understand LRRK biology. The original aims proposed were to... -
Understanding LRRK2 Biology, 2010Biochemical characterization of full length human recombinant LRRK1 and LRRK2
Promising Outcomes of Original Grant:
In our initial application we proposed to take advantage of a lentiviral system recently developed in KULeuven to express full-length, soluble human LRRK1 and...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.